Covid-19 & Liver Cancer
ILCA is committed to providing our community with the most current information on COVID-19 and useful resources including articles and testimonials from healthcare professionals. COVID-19 is an emerging, rapidly evolving situation; therefore, we will continue to provide updated information as soon as it becomes available.
The French Pandemic Resistance Testimonial
Testimonial on how the public hospital St. Louis, in Paris, France, is adapting to the COVID -19 pandemic – “ French Pandemic Resistance.”Download Testimonial
Management Of Hcc During Covid-19: ILCA Guidance
Our expert presenters discussed the current data on COVID-19-related liver disease and the impact of SARS-CoV-2 infection in patients with chronic liver diseases.
Date: Friday, April 17, 2020 at 3:00 PM CEST / 9:00 AM EST
Duration: 1 hour
Management of HCC during COVID-19: ILCA Guidance
ILCA developed a guidance document on recommendations for the management of patients with liver cancer in the COVID-19 pandemic. This guidance document has been put together with the help and knowledge of ILCA Education Committee and Executive Committee.Download ILCA Guidance
ILCA encourages all physicians around the globe
taking care of patients with liver cancer to get involved and submit your cases to these registries, which are not in conflict with any local or national registries whatsoever
We also encourage you to share this effort among your partners and networks. The teams running the registries will credit all contributors in any publications resulting from this work. As the pandemic evolves we will gain insight into better ways of caring for our patients with liver cancer through this and other initiatives.
COVID-Hep is a registry implemented at the University of Oxford, UK to collect data on patients with any sort of liver disease that have been infected with SARS-CoV-2 as confirmed by a positive lab test. SECURE-cirrhosis is a similar registry implemented at the University of North Carolina at Chapel Hill. Both initiatives pretend to answer the question of what are the outcomes of patients with liver diseases (including liver cancer) who become infected with SARS-CoV-2.